CoChat

Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials

Open access
Bogers, Jan P A M, Hambarian, George, Walburgh Schmidt, Niels, Vermeulen, Jentien M, de Haan, Lieuwe · 2023 · Schizophrenia Bulletin
Cited by 58

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background and hypothesis: Although maintenance treatment with antipsychotics protects against psychotic relapse, high doses may hamper recovery. Therefore, dose reduction or discontinuation may be considered in patients with chronic schizophrenia. Here, we identified risk factors for psychotic relapse when doses are reduced. Study Design: We systematically searched MEDLINE, EMBASE, and PsycINFO from January 1950 through January 2021 and reviewed randomized controlled trials (RCTs) that reported relapse rates after antipsychotic dose reduction or discontinuation in patients with chronic schizophrenia. We calculated relative risks (RRs) with 95% confidence intervals (CIs) per person-year and sought to identify potential risk factors for relapse. The study is registered with PROSPERO (CRD42017058296). Study Results: Forty-seven RCTs (54 patient cohorts, 1746 person-years) were included. The RR for psychotic relapse with dose reduction/discontinuation versus maintenance treatment was 2.3 per person-year (95% CI: 1.9 to 2.8). The RR was higher with antipsychotic discontinuation, dose reduction to less than 3–5 mg haloperidol equivalent (HE), or relatively rapid dose reduction (<10 weeks). The RR was lower with long-acting injectable agents versus oral antipsychotic dose reduction. Other factors that increased the risk of psychotic relapse were younger age and short follow-up time. Conclusions: Clinicians should take several risk factors for psychotic relapse into account when considering dose reduction in patients with chronic schizophrenia. Studies of a relatively fast reduction in antipsychotic dose support a minimum dose of 3–5 mg HE. However, if the dose is tapered more gradually, relapses related to medication withdrawal might be avoided, possibly enabling lower-end doses to be achieved.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/schbul/sbac138

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 89

  1. Schneider-Thoma, 2022, Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis, Lancet., 399, 824, 10.1016/S0140-6736(21)01997-8 · DOI · Paper page
  2. Shimomura, 2020, Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms, Schizophr Res., 215, 8, 10.1016/j.schres.2019.09.013 · DOI
  3. Bjornestad, 2020, Antipsychotic treatment—a systematic literature review and meta-analysis of qualitative studies, J Ment Health., 29, 513, 10.1080/09638237.2019.1581352 · DOI
  4. Yoshida, 2021, Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia, Behav Brain Res., 402, 113098, 10.1016/j.bbr.2020.113098 · DOI
  5. Andreasen, 2013, Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study, Am J Psychiatry., 170, 609, 10.1176/appi.ajp.2013.12050674 · DOI · Paper page
  6. Gallego, 2012, Safety and tolerability of antipsychotic polypharmacy, Expert Opin Drug Saf., 11, 527, 10.1517/14740338.2012.683523 · DOI · Paper page
  7. Longdon, 2017, “People with problems, not patients with illnesses”: using psychosocial frameworks to reduce the stigma of psychosis, Isr J Psychiatry Relat Sci, 54, 24
  8. Wang, 2018, Schizophrenia and prospective memory impairments: a review, Clin Neuropsychol., 32, 836, 10.1080/13854046.2017.1406144 · DOI
  9. Harrow, 2012, Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study, Psychol Med., 42, 2145, 10.1017/S0033291712000220 · DOI · Paper page
  10. Moilanen, 2013, Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication. A 10-year follow-up of the Northern Finland 1966 Birth Cohort Study, Eur Psychiatry., 28, 53, 10.1016/j.eurpsy.2011.06.009 · DOI · Paper page
  11. Harrow, 2014, Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study, Psychol Med., 44, 3007, 10.1017/S0033291714000610 · DOI · Paper page
  12. Tandon, 2009, Schizophrenia, “just the facts” 4. Clinical features and conceptualization, Schizophr Res., 110, 1, 10.1016/j.schres.2009.03.005 · DOI · Paper page
  13. Gaebel, 2014, Are there clinically useful predictors and early warning signs for pending relapse?, Schizophr Res., 152, 469, 10.1016/j.schres.2013.08.003 · DOI
  14. Taipale, 2022, Real world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study, Lancet Psychiatry., 9, 271, 10.1016/S2215-0366(22)00015-3 · DOI
  15. Tani, 2020, Factors associated with successful antipsychotics dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials, Neuropsychopharmacology., 45, 887, 10.1038/s41386-019-0573-7 · DOI
  16. Lally, 2015, Antipsychotic medication in schizophrenia: a review, Br Med Bull., 114, 169, 10.1093/bmb/ldv017 · DOI · Paper page
  17. Häfner, 2003, Gender differences in schizophrenia, Psychoneuroendocrinology., 28, 17, 10.1016/S0306-4530(02)00125-7 · DOI · Paper page
  18. Seeman, 2019, Does gender influence outcome in schizophrenia?, Psychiatr Q., 90, 173, 10.1007/s11126-018-9619-y · DOI
  19. Kasckowa, 2001, Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients, Psychiatr Res., 103, 69, 10.1016/S0165-1781(01)00260-8 · DOI
  20. Sugai, 2016, Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia: a nationwide survey, Schizophr Res., 171, 68, 10.1016/j.schres.2016.01.016 · DOI
  21. Nasrallah, 2007, The case for long-acting antipsychotic agents in the post-CATIE era, Acta Psychiatr Scand., 115, 260, 10.1111/j.1600-0447.2006.00982.x · DOI · Paper page
  22. Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ., 339, b2535, 10.1136/bmj.b2535 · DOI · Paper page
  23. Higgins, 2021, Assessing risk of bias in a randomized trial.
  24. Borenstein, 2009, Introduction to Meta-Analysis, 10.1002/9780470743386 · DOI · Paper page
  25. Cook, 2000, Hypothesis testing, Prim Care Respir J., 8, 16, 10.1038/pcrj.2000.6 · DOI
  26. Leucht, 2021, Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis, JAMA Psychiatry., 78, 1238, 10.1001/jamapsychiatry.2021.2130 · DOI · Paper page
  27. Højlund, 2021, Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials, Lancet Psychiatry., 8, 471, 10.1016/S2215-0366(21)00078-X · DOI
  28. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med., 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  29. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ., 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  30. Diamond, 1960, Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage, J Nerv Ment Dis., 131, 247, 10.1097/00005053-196009000-00006 · DOI
  31. Blackburn, 1961, Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics, J Nerv Ment Dis., 133, 303, 10.1097/00005053-196110000-00005 · doi:10.1097/00005053-196110000-00005
  32. Freeman, 1962, Prolonged withdrawal of chlorpromazine in chronic patients, Dis Nerv Syst., 23, 522
  33. Whittaker, 1963, Withdrawal of perphenazine in chronic schizophrenia, Br J Psychiatry., 109, 422, 10.1192/bjp.109.460.422 · DOI · Paper page
  34. Marjerrison, 1964, Withdrawal of long-term phenothiazines from chronically hospitalized psychiatric patients, Can Psychiatr Assoc J., 9, 290, 10.1177/070674376400900404 · DOI
  35. Caffey, 1964, Discontinuation or reduction of chemotherapy in chronic schizophrenics, J Chronic Dis., 17, 347, 10.1016/0021-9681(64)90075-X · DOI
  36. Melnyk, 1966, Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic inpatients, Can Psychiatr Assoc J., 11, 410, 10.1177/070674376601100507 · DOI
  37. Garfield, 1966, Withdrawal of ataractic medication in schizophrenic patients, Dis Nerv Syst., 27, 321
  38. Morton, 1968, A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia, Am J Psychiatry., 124, 1585, 10.1176/ajp.124.11.1585 · DOI
  39. Rassidakis, 1970, Withdrawal of antipsychotic drugs from chronic psychiatric patients, Bull Menninger Clin., 34, 216
  40. Baro, 1970, Maintenance therapy of chronic psychotic patients with a weekly oral dose of R 16341. A controlled double-blind study, J Clin Pharmacol., 10, 330
  41. Hershon, 1972, Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy, Br J Psychiatry., 120, 41, 10.1192/bjp.120.554.41 · DOI
  42. Ota, 1973, A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia, J Clin Pharmacol., 13, 99
  43. Andrews, 1976, A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients, Br J Psychiatry., 128, 451, 10.1192/bjp.128.5.451 · DOI
  44. Lonowski, 1978, Gradual reduction of neuroleptic drugs among chronic schizophrenics. A double-blind controlled study, Acta Psychiatr Scand., 57, 97, 10.1111/j.1600-0447.1978.tb06877.x · DOI
  45. Levine, 1980, Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study, Adv Biochem Psychopharmacol., 24, 483
  46. Lehmann, 1980, Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms, Pharmakopsychiatr Neuropsychopharmakol., 13, 117, 10.1055/s-2007-1019621 · doi:10.1055/s-2007-1019621
  47. Cheung, 1981, Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs?, Br J Psychiatry., 138, 490, 10.1192/bjp.138.6.490 · DOI · Paper page
  48. Odejide, 1982, Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients, J Clin Psychiatry., 43, 195
  49. Lehmann, 1983, Minimal maintenance medication: effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients, Compr Psychiatry., 24, 293, 10.1016/0010-440X(83)90057-3 · DOI
  50. Johnson, 1983, The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences, Acta Psychiatr Scand., 67, 339, 10.1111/j.1600-0447.1983.tb00351.x · DOI · Paper page
  51. Kane, 1983, Low dose medication strategies in the maintenance treatment of schizophrenia, Schizophr Bull., 9, 528, 10.1093/schbul/9.4.528 · DOI
  52. Wistedt, 1983, Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology, Acta Psychiatr Scand., 67, 378, 10.1111/j.1600-0447.1983.tb09718.x · DOI
  53. Channabasavanna, 1987, Penfluridol maintenance therapy in schizophrenia: a controlled study, Indian J Psychiatry., 29, 333
  54. Cookson, 1987, The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime, Int Clin Psychopharmacol., 2, 141, 10.1097/00004850-198704000-00008 · DOI · Paper page
  55. Johnson, 1987, Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia, Br J Psychiatry., 151, 634, 10.1192/bjp.151.5.634 · DOI · Paper page
  56. Hogarty, 1988, Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study, Arch Gen Psychiatry., 45, 797, 10.1001/archpsyc.1988.01800330021002 · DOI · Paper page
  57. Faraone, 1989, Neuroleptic dose reduction in persistently psychotic patients, Hosp Community Psychiatry., 40, 1193
  58. Sampath, 1992, Neuroleptic discontinuation in the very stable schizophrenic patient: relapse rates and serum neuroleptic levels, Hum Psychopharmacol., 7, 355, 10.1002/hup.470070405 · DOI
  59. Inderbitzin, 1994, A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients, Am J Psychiatry., 151, 1753, 10.1176/ajp.151.12.1753 · DOI · Paper page
  60. Hogarty, 1995, Pharmacotherapy of impaired affect in recovering schizophrenic patients, Arch Gen Psychiatry., 52, 29, 10.1001/archpsyc.1995.03950130029004 · DOI · Paper page
  61. Huttunen, 1996, Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics, Psychiatr Serv., 47, 83, 10.1176/ps.47.1.83 · DOI
  62. Hirschowitz, 1997, The dose reduction in schizophrenia (DORIS) study: a final report, Schizophr Res., 23, 31, 10.1016/S0920-9964(96)00074-6 · DOI
  63. Schooler, 1997, Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment, Arch Gen Psychiatry., 54, 453, 10.1001/archpsyc.1997.01830170079011 · DOI · Paper page
  64. Carpenter, 1999, Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks, Am J Psychiatry., 156, 412, 10.1176/ajp.156.3.412 · DOI · Paper page
  65. Volavka, 2000, High-dose treatment with haloperidol: the effect of dose reduction, J Clin Psychopharmacol., 20, 252, 10.1097/00004714-200004000-00020 · DOI
  66. Arato, 2002, A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the ziprasidone extended use in schizophrenia (ZEUS) study, Int Clin Psychopharmacol., 17, 207, 10.1097/00004850-200209000-00001 · DOI · Paper page
  67. Khazaie, 2005, Comparative efficacy of every 2 weeks versus every 6 weeks injections of fluphenazine decanoate, Arch Iranian Med., 8, 109
  68. Uchida, 2006, Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack. An ideal treatment option in terms of the adverse effect, J Clin Psychopharmacol., 26, 50, 10.1097/01.jcp.0000195384.04008.25 · DOI
  69. Kramer, 2007, Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebocontrolled study, J Clin Psychopharmacol., 27, 6, 10.1097/JCP.0b013e31802dda4a · DOI · Paper page
  70. Kane, 2010, Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia, Am J Psychiatry., 167, 181, 10.1176/appi.ajp.2009.07081221 · DOI · Paper page
  71. Wang, 2010, Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial, Am J Psychiatry., 167, 676, 10.1176/appi.ajp.2009.09030358 · DOI · Paper page
  72. Takeuchi, 2013, Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study, Schizophr Bull., 39, 993, 10.1093/schbul/sbt090 · DOI · Paper page
  73. Yamanouchi, 2014, Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method, Int J Neuropsychopharmacol., 18, pyu016, 10.1093/ijnp/pyu016 · DOI
  74. Zhou, 2018, Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: a single-blinded, 52-week, randomized controlled study, J Psychopharmacol., 32, 524, 10.1177/0269881118756062 · DOI
  75. Huhn, 2021, Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial, Eur Arch Psychiatry Clin Neurosci., 271, 293, 10.1007/s00406-020-01109-y · DOI · Paper page
  76. Tiihonen, 2016, Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study, Am J Psychiatry., 173, 600, 10.1176/appi.ajp.2015.15050618 · DOI · Paper page
  77. De Hert, 2015, The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics, CNS Drugs., 29, 637, 10.1007/s40263-015-0269-4 · DOI
  78. Ostuzzi, 2022, Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis, Lancet Psychiatry., 9, 614, 10.1016/S2215-0366(22)00158-4 · DOI
  79. Horowitz, 2022, Confounding of antipsychotic discontinuation studies by withdrawal-related relapse, Schizophr Bull., 48, 294, 10.1093/schbul/sbab146 · DOI
  80. Brandt, 2022, Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis, Lancet Psychiatry., 9, 232, 10.1016/S2215-0366(22)00014-1 · DOI
  81. Horowitz, 2021, Tapering antipsychotic medication: practical considerations, Psychol Med.
  82. Leucht, 2021, Comment & Response to Højlund and colleagues, JAMA Psychiatry., 177, e1
  83. Weiden, 2017, Does half-life matter after antipsychotic discontinuation?, J Clin Psychiatry., 78, e813, 10.4088/JCP.16m11308 · DOI · Paper page
  84. Matuskey, 2016, Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteers, Neuroimage., 130, 241, 10.1016/j.neuroimage.2016.02.002 · DOI
  85. Seamen, 2019, Differential regional decline in dopamine receptor availability across adulthood: linear and nonlinear effects of age, Hum Brain Mapp., 40, 3125, 10.1002/hbm.24585 · DOI · Paper page
  86. Johnstone, 1994, How high is the relapse rate in schizophrenia?, Acta Psychiatr Scand Suppl., 382, 6, 10.1111/j.1600-0447.1994.tb05858.x · DOI
  87. Moncrieff, 2019, Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction), BMJ Open., 9, e030912, 10.1136/bmjopen-2019-030912 · DOI
  88. Horowitz, 2022, Limitations in research on maintenance treatment for individuals with schizophrenia, JAMA Psychiatry., 79, 83, 10.1001/jamapsychiatry.2021.3400 · DOI
  89. Moncrieff, 2020, Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: a systematic review, Schizophr Res., 225, 47, 10.1016/j.schres.2019.08.035 · DOI

Cited by

See all 58

Metadata

Authors
Bogers, J. P. A. M., Hambarian, G., Walburgh Schmidt, N., Vermeulen, J. M., & de Haan, L.
Venue
Schizophrenia Bulletin
Published
2022-10-06
Volume
49
Issue
1
Pages
11-23
ISSN
  • 0586-7614 (ISSN-L)
  • 1745-1701
OpenAlex
W4302304702
Cited by
58
References
14
FWCI
1.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1093/schbul/sbac138
The paper
Bogers, J. P. A. M., Hambarian, G., Walburgh Schmidt, N., Vermeulen, J. M., & de Haan, L. (2023). Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbac138

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.